Investing.com - Financial Markets Worldwide
Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Valeant shares recover a bit after two-day slide

Published 2016-02-23, 09:39 a/m
© Reuters. Valeant shares recover a bit after two-day slide
WFC
-
BHC
-

Feb 23 (Reuters) - Shares of Valeant Pharmaceuticals (N:VRX)
International Inc VRX.N were up more than 6 percent in early
U.S. trading on Tuesday following a two-day selloff, with some
analysts saying that selling of the Canadian drugmaker's stock
had been overdone.
The shares, which were trading at $80.90 shortly after the
opening, had fallen more than 19 percent since Friday after
Wells Fargo (N:WFC) initiated coverage with an "underperform" rating and
a valuation of $65 to $68 per share.
The stock fell further in after-hours trading on Monday
after Laval, Quebec-based Valeant VRX.TO said it would restate
results for 2014 and 2015 after identifying some sales to drug
distributor Philidor Rx Services that should have been
recognized only when the drugs were dispensed to patients.
J.P. Morgan analyst Chris Schott said in a client note that
given the narrow timeframe and the minimal revenue from the
distribution of drugs through Philidor in late 2014 and 2015, he
expected only a limited impact on historical results.
Valeant cut ties with Philidor Rx in October after it was
revealed that the distributor had used aggressive tactics to try
to increase insurer reimbursements, mostly for dermatology
drugs, to help the Valeant inflate revenue.
The restatement will reduce its reported 2014 GAAP earnings
by about 10 cents per share and increase 2015 GAAP earnings by
about 9 cents per share, Valeant said.
"We view this as a marginal impact and certainly not one
that warranted the significant pressure late in the day and
after market yesterday," Stifel analyst Annabel Samimy wrote in
a client note.
Valeant, whose Toronto-listed shares were up 6 percent at
C$110.22, said it would release unaudited fourth-quarter results
next Monday.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.